Curated News
By: NewsRamp Editorial Staff
July 13, 2026
SS Innovations CEO Reveals Strategy to Make Robotic Surgery Affordable
TLDR
- SS Innovations (SSII) gains competitive edge by offering lower-cost surgical robots, expanding market access beyond high-priced platforms.
- The SSi Mantra system reduces robotic surgery costs, supports multiple specialties, and integrates AI and automation for enhanced precision.
- SS Innovations makes robotic surgery affordable and accessible globally, improving patient outcomes and enabling remote expert support.
- SSII has completed over 170 telesurgeries, allowing expert surgeons to guide complex procedures from anywhere in the world.
Impact - Why it Matters
This news matters because it highlights a pivotal shift in surgical robotics: making advanced technology accessible to more hospitals and patients worldwide. If successful, SS Innovations' lower-cost SSi Mantra system could break the monopoly of expensive robotic surgery platforms, potentially reducing healthcare costs and improving outcomes for millions. The emphasis on telesurgery and teleproctoring also points to a future where expert surgical guidance is available remotely, bridging gaps in underserved regions. For investors, this represents a high-growth opportunity in a market projected to expand rapidly as adoption barriers fall.
Summary
In a recent Medsider interview, Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), outlined the company's strategy to democratize robotic surgery by lowering costs and expanding access. SS Innovations, a developer of innovative surgical robotic technologies, aims to challenge the status quo where high equipment costs have limited robotic surgery to well-funded hospitals. The company's SSi Mantra system, designed for multiple specialties including cardiac surgery, is central to this mission. With affordability and accessibility as core priorities, SS Innovations is leveraging artificial intelligence, automation, and new robotic platforms to drive its long-term product roadmap. The company has already installed over 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. Telesurgery and teleproctoring are emerging as key differentiators, enabling expert surgeons to support complex procedures remotely. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
Rather than directly competing with existing robotic surgery giants, SS Innovations focuses on broadening access to hospitals and patients historically unable to adopt robotic surgery due to cost and operational barriers. Dr. Srivastava emphasized that the company's strategy is not just about technology but also about physician training and remote surgical capabilities. The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. The company's progress is underscored by its growing installed base and procedure volume, which serve as proof points for its value proposition. For investors, the competitive advantages behind a product can be as important as financial results, and SS Innovations' focus on affordability and accessibility positions it uniquely in the surgical robotics market.
The news release was distributed by MissionIR, a specialized communications platform that helps IR firms enhance visibility for private and public companies. MissionIR is one of over 75 brands within the Dynamic Brand Portfolio @ IBN, which delivers services such as wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For more information, visit www.MissionIR.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations CEO Reveals Strategy to Make Robotic Surgery Affordable
